Phio Pharmaceuticals Corp (44R3)

1.502
-0.132(-8.08%)
  • Volume:
    0
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    1.502 - 1.502
  • Type:Equity
  • Market:Germany
  • ISIN:US71880W3034
  • WKN:A2PYB0

44R3 Overview

Prev. Close
1.634
Day's Range
1.502-1.502
Revenue
-
Open
1.502
52 wk Range
1.48-3.72
EPS
-
Volume
0
Market Cap
20.69M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,080
P/E Ratio
-
Beta
-
1-Year Change
-27.05%
Shares Outstanding
13,534,389
Next Earnings Date
-
What is your sentiment on Rxi Pharmaceuticals Corp?
or
Vote to see community's results!

Rxi Pharmaceuticals Corp News

Rxi Pharmaceuticals Corp Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Rxi Pharmaceuticals Corp Company Profile

Rxi Pharmaceuticals Corp Company Profile

Employees
10

Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. Phio Pharmaceuticals has collaboration with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.